Glutathione in Mild Cognitive Impairment
Public ClinicalTrials.gov record NCT03493178. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Elderly humans have an increased risk of dementia which begins as mild defects in memory called mild cognitive impairment. Glutathione (GSH), a key endogenous antioxidant has been linked to cognition. This exploratory study will investigate mechanisms linked to GSH for cognitive impairment (and improvement) by studying humans with mild cognitive impairment who will be evaluated 12-weeks after receiving either N-acetylcysteine and glycine (GSH precursors), or receiving alanine, and a further 12-weeks after stopping these supplements.
Study identification
- NCT ID
- NCT03493178
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- Alanine Dietary Supplement
- Glycine Dietary Supplement
- N-acetylcysteine (NAC) Dietary Supplement
Dietary Supplement
Eligibility (public fields only)
- Age range
- 55 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 18, 2018
- Primary completion
- May 29, 2025
- Completion
- Dec 30, 2026
- Last update posted
- Mar 23, 2026
2018 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Baylor College of Medicine | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Mild Cognitive Impairment trials
Other public records listing Mild Cognitive Impairment. Sorted by last update posted; newest first. Not a recommendation.
- NCT07785648: Mindfulness-Based Cognitive Therapy Vs. the Health Enhancement Program for Chronic Pain and Early Cognitive Decline; The Feeling of Being Pilot RCT Not yet recruiting
- NCT07773493: A Mobile Informatics Solution to Assist Caregivers in Care Coordination and Monitoring Social Engagement Not yet recruiting
- NCT05532657: ACHIEVE Brain Health Follow-Up Study Active, not recruiting
- NCT07701785: Superior Parietal iTBS for PD-MCI Recruiting
- NCT05904132: Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease Recruiting
- NCT04765137: Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03493178, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 23, 2026 · Synced Jul 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03493178 live on ClinicalTrials.gov.